Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Low molecular weight heparins].

G Agnelli1, B Cosmi

  • 1Istituto di Semeiotica Medica, Università di Perugia.

Medicina (Florence, Italy)
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Low molecular weight heparins (LMWHs) offer effective antithrombotic therapy for preventing deep-vein thrombosis (DVT) in various patient groups. Further research is needed to establish optimal dosing and confirm safety profiles compared to standard heparin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.

BMC infectious diseases·2023
Same author

Deep Vein Thrombosis in Europe-Health-Related Quality of Life and Mortality.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2019
Same author

Oxygen saturation or respiratory rate to improve risk stratification in hemodynamically stable patients with acute pulmonary embolism.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work.

Thrombosis research·2018
Same author

State of play and future direction with NOACs: An expert consensus.

Vascular pharmacology·2018
Same author

Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.

Journal of thrombosis and haemostasis : JTH·2018
Same journal

[Infectious diseases].

Medicina (Florence, Italy)·1990
Same journal

[The human genome project: reflections of an expert].

Medicina (Florence, Italy)·1990
Same journal

[Decrease in notifications of AIDS dementia complex in 1989-1990 in Italy: possible role of the early treatment with zidovudine].

Medicina (Florence, Italy)·1990
Same journal

[Clinical usefulness of a new echocardiographic window: the transesophageal approach].

Medicina (Florence, Italy)·1990
Same journal

[Skin disease in Basedow's disease].

Medicina (Florence, Italy)·1990
Same journal

[Prognostic factors in Raynaud's phenomenon: usefulness of antinuclear antibodies and of periungual capillaroscopy].

Medicina (Florence, Italy)·1990
See all related articles

Area of Science:

  • Pharmacology and Therapeutics
  • Hematology

Background:

  • Low molecular weight heparins (LMWHs) are derived from unfractionated heparin (UFH) through fragmentation or fractional procedures.
  • LMWHs aim to provide a more effective and safer antithrombotic agent than standard heparin (SH).
  • Structural heterogeneity among LMWHs may explain observed clinical variations in efficacy and safety.

Purpose of the Study:

  • To review the efficacy and safety of various Low Molecular Weight Heparins (LMWHs) in preventing and treating deep-vein thrombosis (DVT).
  • To compare the antithrombotic effects of LMWHs against standard heparin (SH) and placebo in different clinical settings.
  • To evaluate the established and potential roles of LMWHs in prophylaxis and treatment of thromboembolic events.

Main Methods:

  • Review of clinical trials and studies investigating LMWHs for deep-vein thrombosis (DVT) and pulmonary embolism prevention.

Related Experiment Videos

  • Comparison of specific LMWH compounds (e.g., CY 216, PK 10169, ORG 10172, KABI 2165) against standard heparin (SH) and placebo.
  • Analysis of LMWH use in diverse patient populations including those undergoing surgery, hemodialysis, or with stroke.

    • Main Results:

    • LMWHs are effective antithrombotic agents for DVT prevention in general surgery compared to placebo.
    • Certain LMWHs, like CY 216, demonstrate comparable or superior efficacy to standard heparin (SH) with less frequent dosing.
    • Evidence supports PK 10169 efficacy in preventing DVT after hip surgery, with some studies showing superiority over SH; ORG 10172 and KABI 2165 also show DVT prevention efficacy in stroke patients.

    Conclusions:

    • LMWHs are effective in preventing deep-vein thrombosis (DVT) in specific patient populations, with some showing improved efficacy over standard heparin (SH).
    • The promising experimental findings of reduced bleeding with LMWHs compared to SH require further clinical validation.
    • The optimal dose for the best risk-benefit ratio for each LMWH compound needs to be established before widespread adoption for prophylaxis or treatment.